Here are the top 5 biosimilar articles for the week of November 1, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of November 1, 2021.
Number 5: Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the Academy of Managed Care Pharmacy (AMCP) 2021 Nexus meeting.
Number 4: Year-over-year biosimilar revenues climbed 10% at Biocon Biologics amid a general reduction in income (-18%), the company said in an earnings statement.
Number 3: Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to much more robust savings in recent years, said Leslie Fish, RPh, PharmD, vice president of pharmacy at IPD Analytics, at the AMCP 2021 Nexus meeting.
Number 2: An Emory pharmacy expert talked about the timing of switching to biosimilars, the Biosimilars Forum recommends biosimilars incentives, and Samsung Bioepis reaches a milestone.
Number 1: The arrival of Susvimo, an ocular implant for treatment of macular degeneration, poses a challenge for ophthalmic reference products and biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?